Clinical Trials Logo

Hypoparathyroidism clinical trials

View clinical trials related to Hypoparathyroidism.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06020820 Completed - Clinical trials for Post-Thyroidectomy Hypoparathyroidism

Effectiveness Of Cervical Rehabilitation Program After Thyroidectomy

Start date: October 25, 2022
Phase: N/A
Study type: Interventional

The aim of this research is to determine the Effects of cervical rehabilitation program on neck pain, ROM and disability after thyroidectomy. Randomized controlled trials will be done at Pakistan ordinance factory (POF) Hospital. The sample size will be 52. The subjects were divided in two groups, with 26 subjects in Group A and 26 in Group B. Study duration was of 6 months. Sampling technique applied was Non probability Convenience Sampling technique. Both males and females of aged 30-50 years with thyroidectomy were included. Tools used in the study are Numeric Pain Rating Score (NPRS), goniometer and neck disability index (NDI).

NCT ID: NCT05684029 Completed - Thyroid Cancer Clinical Trials

Near-Infrared Autofluorescence With PTH Test Strip as an SOP of Parathyroid in Thyroid Surgery

PTFINDER
Start date: November 1, 2022
Phase:
Study type: Observational

This is a prospective study aiming to establish near-infrared autofluorescence technology and PTH test strip as a standardized process for finding and identifying parathyroid glands in thyroid surgery.

NCT ID: NCT05239221 Completed - Clinical trials for Chronic Hypoparathyroidism

AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism

Start date: September 7, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is investigating the safety, tolerability, pharmacodynamics and pharmacokinetics of AZP-3601 following single and repeated administration in both healthy volunteers and patients with chronic hypoparathyroidism (cHP) The protocol includes 3 parts: - Part A: first-in-human single ascending dose (SAD) study in healthy volunteers - Part B: multiple ascending dose (MAD) study with 2 weeks of treatment in healthy volunteers - Part C: open-label MAD study with a total treatment duration of 3 months in patients with cHP.

NCT ID: NCT05214274 Completed - Clinical trials for Chronic Hypoparathyroidism

Multicenter Registry Study of Chronic Hypoparathyroidism in Chinese Adults

PaTHwayR
Start date: January 10, 2022
Phase:
Study type: Observational

This multicenter registry study aims to understand the status of diagnosis and treatment, quality of life, medical costs and unmet medical needs of adult patients with chronic hypoparathyroidism in China.

NCT ID: NCT05043584 Completed - Thyroidectomy Clinical Trials

Near-infrared Autofluorescence (NIRAF)-Guided Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Institutions

Start date: September 15, 2021
Phase: N/A
Study type: Interventional

Hypoparathyroidism is the most frequent complication in total thyroidectomy. The use of near-infrared autofluorescence (NIRAF) intraoperatively, seems to reduce the rate of transient hypoparathyroidism. Unfortunately, no effect on permanent hypoparathyroidism has been shown. In order to cover every aspect of the impact of NIRAF in thyroid surgery, an evaluation in low-volume, non-parathyroid institutions is needed. This is the overall aim of our current studies. The objective of this specific study is to evaluate the impact of NIRAF on immediate, transient and permanent hypoparathyroidism following total thyroidectomy in low-volume, non-parathyroid institutions.

NCT ID: NCT04750460 Completed - Clinical trials for Secondary Hyperparathyroidism

Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).

TeriCa
Start date: March 1, 2021
Phase: Phase 3
Study type: Interventional

This is a pilot randomized controlled trial aimed to evaluate the effect of teriparatide on the clinical course of hypocalcemia after parathyroidectomy for secondary hyperparathyroidism in dialysis-dependent patients.

NCT ID: NCT04690842 Completed - Clinical trials for Hypoparathyroidism Postprocedural

Improving Safety in Pediatric Thyroidectomy by PTH Measurements

Start date: June 2014
Phase:
Study type: Observational

We implemented a previously reported algorithm based on intra-postoperative PTH measurements with selected cut-off values, both to predict post-thyroidectomy hypoparathyroid hypocalcemia, and to guide postsurgical management. The objective of the study was to assess if this strategy was useful to reduce hypocalcemia, post-surgery calcium sampling and hospitalization length.

NCT ID: NCT04671719 Completed - Hyperparathyroidism Clinical Trials

Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities

GNAS-AUTAX
Start date: March 10, 2021
Phase:
Study type: Observational

PTH secretion defects (grouped under the name hypoparathyroidism) are due to abnormalities in the PTH gene, abnormalities in the development of the parathyroid glands which synthesize PTH or abnormalities of the calcium sening receptor whose role is to adapt PTH level to ambient calcium level. In contrast, primary hyperparathyroidism in children is also exceptional; expressed by hypercalcemia, with a renal and bon risk. Pseudo-hypoparathyroidism, now known under the term inactivating PTH / PTHrP Signaling Disorder or iPPSD, are rare pathologies characterized by resistance to the action of PTH sometimes associated with other symptoms, in particular chondrodysplasia. They are linked to a defect in the action of a factor in the signaling pathway of G protein-coupled receptors that activate the production of cyclic AMP (cAMP). IPPSDs are most often due to a molecular defect in the GNAS gene, subject to parental imprint. Fibrous dysplasia / McCune-Albright syndrome is a rare disease caused by somatic "gain-of-function" mutations in the GNAS gene located on chromosome 20q13 leading to activation of the protein Gαs and inappropriate production of intracellular cyclic adenosine monophosphate (cAMP). The clinical phenotype is determined by the location and extent of the tissues affected by this mutation. Autotaxin (ATX) is a protein secreted by different tissues including the liver, fatty tissue, and bone. Today, ATX is described as the major source of LPA in the bloodstream. LPA interacts with one of its receptors on the surface of the cell membrane. Depending on the receptor engaged, one or more Gα subunits (G12 / 13, GQ, Gi / o or Gs) will activate multiple cell signaling pathways. In bone, ATX is expressed by osteoclasts and osteoblasts. Recent laboratory data have shown that PTH stimulates ATX expression in osteoblasts in a dose-dependent manner. The objective of this study is to provide clinical proof of concept that the PTH / Gαs / ATX pathway is truly significant in physiology and pathology, by studying the full spectrum of PTH and GNAS pathologies. If this proof of concept is obtained, therapeutic applications will probably be possible in the long term.

NCT ID: NCT04604808 Completed - Clinical trials for Hypoparathyroidism Postprocedural

Study on the Effects of Hypoparathyroidism on Post-thyroidectomy Health-related Quality of Life (QoL-hPTP)

QoL-hPTP
Start date: October 1, 2020
Phase:
Study type: Observational

Our study will evaluate the health related quality of life (HRQoL) after a thyroidectomy and the relevance of postoperative hypoparathyroidism. The patients submitted to a total thyroidectomy will be evaluated with three questionaries (SF-36, Hospital HADS and a specifically designed Likert-type questionary about the intensity of hypoparathyroidism symptoms). The first evaluation will be before the surgery, and the other two will be completed a week and a month after the procedure.

NCT ID: NCT04569604 Completed - Hypoparathyroidism Clinical Trials

QoL and Cognitive Function in Patients With Hypoparathyroidism

MR-hypoPT
Start date: October 1, 2019
Phase:
Study type: Observational

Hypoparathyroidism (HypoPT) is a disease with inadequate production of parathyroid hormone (PTH) from the parathyroid glands leading to hypocalcemia. The most common form is postsurgical HypoPT due to neck surgery resulting in removed or damaged parathyroid glands. HypoPT is a complex disease with a reduced Quality of life, mild cognitive impairment and in some patients have brain calcifications. The aim of the present study is to investigate the cognitive function in patients with postsurgical and non-surgical (HypoPT) by neuropsychological assessments and magnetic resonance imaging (MRI). The investigators will apply a contrast-enhanced MRI based method to HypoPT patients and age- and gender matched controls to examine whether capillary dysfunction can be detected, and whether symptom severity across patients correlates with the degree of capillary dysfunction in certain brain regions. To our knowledge there have been no previous studies on cognitive impairment and its origin in patients with HypoPT. The investigators hypothesize that the symptoms of HypoPT patients represent various degrees of capillary dysfunction, which interfere with their brain function.